Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
480
datasets available to search
ShareScore release 0.7.1
Dataset results
480 results for “Hormone Receptors”
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
ClinicalTrials.gov study NCT01225172. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
ClinicalTrials.gov study NCT00248170. IPD Sharing: Not stated. Countries: 20. Publications: 0.
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
ClinicalTrials.gov study NCT01790126. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced
ClinicalTrials.gov study NCT02964507. IPD Sharing: YES. Countries: 7. Publications: 0.
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
ClinicalTrials.gov study NCT00499681. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemot
ClinicalTrials.gov study NCT02971748. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
ClinicalTrials.gov study NCT03280563. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
ClinicalTrials.gov study NCT06374459. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
ClinicalTrials.gov study NCT04683679. IPD Sharing: YES. Countries: 1. Publications: 0.
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
ClinicalTrials.gov study NCT00534417. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
ClinicalTrials.gov study NCT00481845. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
ClinicalTrials.gov study NCT00461773. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis
ClinicalTrials.gov study NCT05153187. IPD Sharing: NO. Countries: 1. Publications: 0.
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
ClinicalTrials.gov study NCT00577122. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
ClinicalTrials.gov study NCT07400523. IPD Sharing: YES. Countries: 0. Publications: 0.
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
ClinicalTrials.gov study NCT00634634. IPD Sharing: NO. Countries: 1. Publications: 0.
Neo-Adjuvant Endocrine Therapy in Post-Menopausal Hormone Receptor Positive HER 2 Neu Negative Node Positive Early-Stage Breast Cancer Patients With One Year of Letrozole.
ClinicalTrials.gov study NCT07394946. IPD Sharing: NO. Countries: 1. Publications: 0.
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
ClinicalTrials.gov study NCT02003209. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania
ClinicalTrials.gov study NCT05438511. IPD Sharing: YES. Countries: 2. Publications: 0.
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer
ClinicalTrials.gov study NCT03132467. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.